Business Wire

GA-BIOLOG-ID

28.5.2019 14:02:08 CEST | Business Wire | Press release

Share
The Hoxworth Blood Center and Biolog-id signed a partnership contract to manage blood products in Cincinnati metropolitan area

The Biolog-id solution was first implemented in 2018 to focus on the distribution and inventory management of Platelet Concentrates (PCs) between the Blood Center and 4 hospitals located nearby.

In 2019, it is also covering the Phenotyped Red Blood Cell Concentrates (RBCs) managed by the Hoxworth Blood Center’s Immunohematology Reference Laboratory (IRL). The laboratory provides testing and consultation to assist hospitals in solving patients’ red blood cell serological problems.

The implementation of the Biolog-Transfusion® in Hoxworth Blood Center ensures the availability of platelets concentrates and their on-time delivery while reducing the risk of wastage by implementing a safe return of unused products and more particularly to reduce the transportation costs from the Blood Center to the hospitals, control the shelf life of the remote platelets stock sitting in the hospitals, allow the unused products to return and be reassigned in a timely manner before expiration, reduce wastage of products overall, improve accuracy and documentation of inventory and better comply with regulatory requirements.

“As of today, we are satisfied with the BIOLOG-ID solution for platelets as well as their professional and committing team ” says Jose A. Cancelas, Director of Hoxworth Blood Center.

Extension on the overall blood product production and supply is under consideration by Hoxworth Blood Center.

About Hoxworth Blood Center
Hoxworth Blood Center is a public institution belonging to the University of Cincinnati (OH). Hoxworth Blood Center collects ~90,000 donations per year and serves more than 30 hospitals and healthcare centers in the States of Ohio, Indiana and Kentucky.

About Biolog-id
Biolog-id has developed a patended smart solution for the management and traceability of sensitive health products, based on RFID technology: blood products, plasma for fractionation and chemotherapy. Biolog-id operates in North America, Europe, Middle East, India and Asia Pacific region and has 90 employees worldwide. Biolod-id is owned by its founder, managers and the Xerys Funds
www.biolog-id.com

Contact:

Amit Mayer +1 404 953 3169 amit.mayer@biolog-id.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Gencom Acquires Rosewood London, Expanding Its Footprint With Its First Luxury Hotel Acquisition in Europe3.11.2026 19:05:00 CET | Press release

Located in one of the world’s most prestigious hospitality corridors, the acquisition of the 308-key hotel represents a major milestone in the firm’s international growth. Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London, the landmark 308-key luxury hotel situated at 252 High Holborn in Central London. The acquisition strengthens Gencom’s global hospitality investment platform and expands its presence in Europe through its first luxury hotel asset in London. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103137897/en/ Gencom, a U.S.-based investment firm that owns and develops prized real estate around the world, announces the acquisition of Rosewood London in Central London London is one of the world’s most supply-constrained hospitality markets, supported by year-round demand from both leisure and business travelers. The acquisi

SGCA Honours Communication Excellence Across Asia, Europe and the Arab World3.11.2026 16:52:00 CET | Press release

His Highness Sheikh Dr Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, honoured winners of the 13th Sharjah Government Communication Award (SGCA), organised by the Sharjah Government Media Bureau (SGMB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103972039/en/ SGCA honours communication excellence across Asia, Europe and the Arab world (Photo: AETOSWire) Winners represented China, India, Thailand, Ukraine and the Arab world. Some 433 entries from 31 countries across four continents passed initial screening. The award covered 23 categories across five sectors, including six partner awards. His Excellency Tariq Saeed Allay, Director General of SGMB, highlighted the award’s growth under the vision of His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, noting that it had attracted more than 9,500 entries over five year

BioLife to Showcase Oral Peptide Delivery Technology During London Life Sciences Week3.11.2026 16:03:00 CET | Press release

Company to highlight granted patent portfolio, preclinical semaglutide data and potential applications across future peptide medicines at LSX Investival BioLife Products Limited today announced its participation in London Life Sciences Week, where it will highlight its patented oral peptide delivery technology and recent advances in its intellectual property portfolio. BioLife will present at the LSX Investival Showcase on Monday, November 16, 2026, from 3:15 to 3:30 p.m. GMT, at Old Billingsgate, London. The presentation will be led by Former US Ambassador James P. Cain, Strategic Advisor to the Chairman & Founder, alongside Ludivine Delattre, Business and Corporate Relations, and will highlight the scientific journey behind the technology and its potential applications. BioLife is focused on developing a novel approach to delivering peptide therapeutics orally. Built on over 35 years of pharmaceutical effervescence expertise and two decades of oral peptide research by founder and inv

Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan3.11.2026 16:00:00 CET | Press release

Five-year agreement builds on Sceye’s successful stratospheric connectivity tests in Japan and advances full-scale deployment of HAPS as stratospheric infrastructure and a key pillar of SoftBank’s strategy for a Ubiquitous Network Sceye, a U.S. aerospace and material science company building High Altitude Platform Systems (HAPS) for stratospheric infrastructure, today announced a five-year Master Services Agreement (MSA) with SoftBank Corp. (TOKYO:9434, “SoftBank”) to manufacture, launch, and operate a fleet of Sceye’s HAPS over Japan with the aim of achieving nationwide coverage. This agreement advances the companies’ partnership from flight demonstrations toward full-scale stratospheric infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103391128/en/ Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan Sceye’s HAPS will form a key pillar of SoftB

Organigram to Acquire Aurora andEstablish a Global Cannabis Leader3.11.2026 15:16:00 CET | Press release

Organigram to acquire Aurora for C$7.80 per Aurora Common Share; Aurora shareholders will have the option to receive such Consideration in cash, Organigram shares or a combination of both, subject to proration. Transaction provides Aurora shareholders with certainty of value, meaningful immediate liquidity and participation in the combined entity Offer represents a 93% premium to Aurora’s Unaffected Share Price on August 10, 20261 and a 21% premium to the implied value of the unsolicited Curaleaf Hostile Bid as of November 2, 20262, unanimously rejected by Aurora’s Board of Directors Organigram shareholders to participate alongside Aurora shareholders in a company with greater scale, enhanced supply chain certainty, global footprint and diversification The combined company will own and operate five EU-GMP certified production and distribution facilities and bring world-class innovation to existing and new markets to meet international demand and support global market share expansion Th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye